Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, and the mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.

Abstract: The problem addressed by the present invention is to provide a method for suppressing cold flow during packaging or application, regardless of the properties or concentration of a drug, in a patch containing a drug and an acrylic adhesive base in an adhesive layer. The present invention relates to a method for suppressing cold flow of a patch equipped with a support layer and an adhesive layer containing a drug and an acrylic adhesive base, wherein the method causes calcium silicate to be contained in the adhesive layer.

Abstract: Stretchable, occlusive backing layers for transdermal drug delivery systems are disclosed, that maintain occlusivity after stretching. The backing layers are comprised of a stretchable backing material provided with an occlusive coating comprising a styrene-isoprene-styrene block copolymer and tackifier. Also described are transdermal drug delivery systems having such backing layers, including transdermal drug delivery systems for non-steroidal anti-inflammatory drugs (NSAIDs), and methods of making and using such backing layers and transdermal drug delivery systems.

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains a rubber-based adhesive base and a silicone-based adhesive base, and a mass ratio of the rubber-based adhesive base to the silicone-based adhesive base (the mass of the rubber-based adhesive base:the mass of silicone-based adhesive base) in the adhesive layer is 9.5:0.5 to 1.9:8.1.

Abstract: The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m2·24 hours or more, and the adhesive layer comprises a drug, dimethylsulfoxide and an adhesive. Such a patch does not fall off easily even after long wear.

Abstract: The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m2·24 hours or more, and the adhesive layer comprises a drug, dimethylsulfoxide and an adhesive. Such a patch does not fall off easily even after long wear.

Abstract: Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix.

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains an adhesive base and an antioxidant containing a sulfur atom in its molecule.

Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains at least one drug selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof and a silicone-based adhesive base, and a mass per unit area of the adhesive layer is 30 to 90 g/m2.

Abstract: The present invention addresses the problem of providing a methylphenidate-containing transdermal patch in which cold flow beyond the edge of the patch containing methylphenidate is inhibited, and which has sufficient physical properties as a preparation, and excellent handleability. The present invention pertains to: a transdermal patch comprising a backing layer and an adhesive layer, wherein the adhesive layer contains methylphenidate, a rubber-based adhesive agent, and an acrylic adhesive agent, and the mixing ratio of the rubber-based adhesive agent to the acrylic adhesive agent is 9:1 to 1:9, and a production method for the transdermal patch.

Abstract: The present invention addresses the problem of providing a methylphenidate-containing patch that maintains a suitable adhesion to skin over a long period of time and has a sustained drug efficacy and an excellent handeleability. The present invention relates to a patch comprising a backing layer and an adhesive layer, wherein the adhesive layer contains methylphenidate, a rubber-based adhesive base, and a tackifying resin. The rubber-based adhesive base contains a styrene-isoprene-styrene block copolymer, and the tackifying resin contains a terpene-based resin and an alicyclic saturated hydrocarbon resin. The present invention further relates to a method for producing the patch.

Abstract: A problem addressed by the present invention is to provide an adhesive patch, which contains an acrylic adhesive base material, is easy to handle, prevents cold flow independently of physical properties and concentrations while being kept in a packaging material or being adhered, and during storage, keeps the drug in the adhesive patch stable and maintains the suitable administration form of the drug over a long period so that the drug can provide sufficient medicinal effect for a long time. The present invention relates to an adhesive patch provided with a backing layer and an adhesive agent layer, the adhesive agent layer containing a drug, an acrylic adhesive base material, and calcium silicate. The present invention also relates to a method for producing the adhesive patch.

Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, and the mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains a rubber-based adhesive base and a silicone-based adhesive base, and a mass ratio of the rubber-based adhesive base to the silicone-based adhesive base (the mass of the rubber-based adhesive base:the mass of silicone-based adhesive base) in the adhesive layer is 9.5:0.5 to 1.9:8.1.

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains an adhesive base and an antioxidant containing a sulfur atom in its molecule.

Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains at least one drug selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof and a silicone-based adhesive base, and a mass per unit area of the adhesive layer is 30 to 90 g/m2.

Abstract: The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m2·24 hours or more, and the adhesive layer comprises a drug, dimethylsulfoxide and an adhesive. Such a patch does not fall off easily even after long wear.

Abstract: Stretchable, occlusive backing layers for transdermal drug delivery systems are disclosed, that maintain occlusivity after stretching. The backing layers are comprised of a stretchable backing material provided with an occlusive coating comprising a styrene-isoprene-styrene block copolymer and tackifier. Also described are transdermal drug delivery systems having such backing layers, including transdermal drug delivery systems for non-steroidal anti-inflammatory drugs (NSAIDs), and methods of making and using such backing layers and transdermal drug delivery systems.

Abstract: Described are transdermal drug delivery systems for extended delivery of a therapeutic agent in the form of a flexible finite system for topical application, comprising (i) a polymer matrix comprising a therapeutic agent and (ii) a face adhesive layer disposed on a skin-contacting side of the polymer matrix comprising a rubber-based polymer. Methods of making and using such systems also are described.

Abstract: A support film for tape which is used for a tape, the support film for tape includes: a film-shaped support formed of polyurethane; and a barrier layer which includes a water-soluble polymer compound and montmorillonite and is formed on one surface of the support. The support film for tape has a percentage content of the montmorillonite in the barrier layer is equal to or more than 2 percent by weight and equal to or less than 22 percent by weight.